Cancer Therapy News and Research

RSS

Oral agent alendronate may help men with prostate cancer suffering from bone loss

Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott.

27 Feb 2006

Multikine treatment increases survival in cancer patients

CEL-SCI Corporation has announced positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine in a Phase II clinical trial.

21 Feb 2006

Effects of cancer treatment among children of survivors

Can the high doses of chemotherapy and radiation that young cancer patients receive cause inherited health problems for their children? Vanderbilt-Ingram Cancer Center member, John Boice, Sc.D., and an international team of colleagues have just been awarded a $4 million grant from the National Cancer Institute to try to find out.

21 Feb 2006

Monoclonal antibody targets key tumor growth factor

Monoclonal antibody targets key tumor growth factor; Successfully causes brain tumor regression and improves animal survival

19 Feb 2006

Botox finds a use in cancer treatment

The cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy, providing an open door for chemotherapy and radiation treatments, according to a study published in the Feb. 15 issue of Clinical Cancer Research.

17 Feb 2006

Inactivating Rad9 protien could make cancer cells easier to kill with ionizing radiation

The researchers found that Rad9, previously considered a "watchman" that checks for DNA damage, is actually a "repairman" that fixes dangerous breaks in the DNA double helix. They found Rad9 is especially active in telomeres, the protective ends of chromosomes.

17 Feb 2006

Study identifies compounds that overcome a specific type of resistance to chemotherapeutic-induced apoptosis

Treatment of human cancer is often impeded when cancer cells develop resistance to drugs that are designed to induce a type of programmed cell death called apoptosis.

16 Feb 2006

Tetracaine mouthwash helps with pain linked to head and neck cancer

Doctors in Italy are studying whether a new type of mouthwash will help alleviate pain for patients suffering from head and neck cancer who were treated with radiation therapy, according to a study published in the International Journal of Radiation Oncology-Biology-Physics

13 Feb 2006

Chink in cancer's armor

Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.

13 Feb 2006

Flow technique - a quick and simple technique to characterize breast cancer cells

A quick and simple technique to characterize breast cancer cells may expedite and improve treatment decisions, researchers from the University of Illinois at Chicago report in the journal of Experimental and Molecular Pathology.

12 Feb 2006

PET imaging has the potential to improve cancer care management

A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment

7 Feb 2006

Alternative method to produce heparin

Researchers at Rensselaer Polytechnic Institute and University of North Carolina at Chapel Hill have discovered an alternative way to produce heparin, a drug commonly used to stop or prevent blood from clotting.

7 Feb 2006

Vaccine against ricin safe and effective

Scientists at the University of Texas Southwestern Medical Center at Dallas, say a vaccine against the deadly toxin ricin is safe and effective.

31 Jan 2006

Study may provide new hope for cancer patients

New study by Mount Sinai researchers may lead to improved stem cell therapies for patients with compromised immune systems due to intensive cancer therapy or autoimmune disease. The study is published in this week's issue of Cell.

27 Jan 2006

Breast ducts - A new site for cancer treatment!

Johns Hopkins Kimmel Cancer Center researchers are studying whether delivering chemotherapy drugs directly to breast "plumbing" might make treatment of early breast cancer easier on the patient and at least as good as surgery or radiation.

26 Jan 2006

Tumor cell growth depends on interactions with its microenvironment

An EU funded Specific Targeted Research Project (STREP) entitled "Tumor-Host Genomics" has been launched at the University of Helsinki, Finland.

26 Jan 2006

No link between reduced cancer risk and Omega-3 fatty acids

Researchers in the U.S. have found in a comprehensive review of numerous studies, that there is little evidence to support the belief that the consumption of omega-3 fatty acids reduces risk of cancer.

26 Jan 2006

Omega-3 fatty acids appear not to reduce cancer risk

A review of numerous studies finds no strong evidence indicating a significantly reduced risk of cancer associated with the consumption of omega-3 fatty acids, according to an article in the January 25 issue of JAMA: The Journal of the American Medical Association.

25 Jan 2006

Guidelines for International Breast Health and Cancer Control

Specific recommendations for improving breast-health care and cancer treatment in countries with limited resources have been published by the Breast Health Global Initiative (BHGI), an international coalition of doctors, scientists, policy makers and advocates led by Fred Hutchinson Cancer Research Center and the Susan G. Komen Breast Cancer Foundation.

25 Jan 2006

Bexarotene shows promise in cancer treatment.

Researchers at Washington University School of Medicine in St. Louis now report that a compound related to vitamin A shows promise in preventing or slowing tumor growth in mice prone to lung cancer. The compound, called bexarotene, doesn't cause the severe skin irritations that have limited the use of other vitamin A derivatives in cancer therapies.

18 Jan 2006